Mannose-binding lectin genotype influences frequency and duration of infectious complications in children with malignancy

Journal of Pediatric Hematology/Oncology

Volumn 35, Issue 1, 2013, Pages 69-75

  Dommett, Rachel ^a   Chisholm, Julia ^a   Turner, Malcolm ^b   Bajaj Elliott, Mona ^a   Klein, Nigel J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

cancer; children; infection; innate immunity; mannosebinding lectin

Indexed keywords

MANNOSE BINDING LECTIN; MANNOSE BINDING LECTIN 2;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; DISEASE DURATION; DISEASE SEVERITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HETEROZYGOTE; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; INFANT; INFECTION RISK; INFECTION SENSITIVITY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MANNOSE BINDING LECTIN 2 GENE; MIXED INFECTION; MULTICENTER STUDY (TOPIC); NONHODGKIN LYMPHOMA; PATHOGENESIS; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION; WILD TYPE;

ADOLESCENT; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DISEASE SUSCEPTIBILITY; FEMALE; FEVER; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; INFANT; LENGTH OF STAY; LONDON; MALE; MANNOSE-BINDING LECTIN; NEOPLASMS; NEUTROPENIA; PHENOTYPE; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84871754060     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31827076e5     Document Type: Article

References (34)

1. Sankila R, Martos Jimenez MC, Miljus D, et al. Geographical comparison of cancer survival in European children (1988- 1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42:1972-1980.
2. Basu SK, Fernandez ID, Fisher SG, et al. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol. 2005;23:7958-7966.
3. Graubner UB, Porzig S, Jorch N, et al. Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50:259-263.
4. Hartel C, Deuster M, Lehrnbecher T, et al. Current approaches for risk stratification of infectious complications in pediatric oncology. Pediatr Blood Cancer. 2007;49:767-773.
5. Neth O, Hann I, Turner MW, et al. Deficiency of mannosebinding lectin and burden of infection in children with malignancy: a prospective study. Lancet. 2001;358:614-618.
6. Vekemans M, Robinson J, Georgala A, et al. Low mannosebinding lectin concentration is associated with severe infection in patients with hematological cancer who are undergoing chemotherapy. Clin Infect Dis. 2007;44:1593-1601.
7. Dommett RM, Klein N, Turner MW. Mannose-binding lectin in innate immunity: past, present and future. Tissue Antigens. 2006;68:193-209.
8. Sumiya M, Super M, Tabona P, et al. Molecular basis of opsonic defect in immunodeficient children. Lancet. 1991;337:1569-1570.
9. Lipscombe RJ, Sumiya M, Hill AV, et al. High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. Hum Mol Genet. 1992;1:709-715.
10. Madsen HO, Garred P, Kurtzhals JA, et al. A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics. 1994;40:37-44.
11. Madsen HO, Garred P, Thiel S, et al. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol. 1995;155: 3013-3020.
12. Madsen HO, Satz ML, Hogh B, et al. Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J Immunol. 1998;161:3169-3175.
13. Peterslund NA, Koch C, Jensenius JC, et al. Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet. 2001;358:637-638.
14. Frakking FN, Israels J, Kremer LC, et al. Mannose-binding lectin (MBL) and the risk for febrile neutropenia and infection in pediatric oncology patients with chemotherapy. Pediatr Blood Cancer. 2011;57:89-96.
15. Lausen B, Schmiegelow K, Andreassen B, et al. Infections during induction therapy of childhood acute lymphoblastic leukemia - no association to mannose-binding lectin deficiency. Eur J Haematol. 2006;76:481-487.
16. Frakking FN, van de Wetering MD, Brouwer N, et al. The role of mannose-binding lectin (MBL) in paediatric oncology patients with febrile neutropenia. Eur J Cancer. 2006;42: 909-916.
17. Schlapbach LJ, Aebi C, Otth M, et al. Serum levels of mannose-binding lectin and the risk of fever in neutropenia pediatric cancer patients. Pediatr Blood Cancer. 2007;49: 11-16.
18. Mullighan CG, Heatley S, Doherty K, et al. Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood. 2002;99:3524-3529.
19. Rocha V, Franco RF, Porcher R, et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood. 2002;100:3908-3918.
20. Bergmann OJ, Christiansen M, Laursen I, et al. Low levels of mannose-binding lectin do not affect occurrence of severe infections or duration of fever in acute myeloid leukaemia during remission induction therapy. Eur J Haematol. 2003;70:91-97.
21. Kilpatrick DC, McLintock LA, Allan EK, et al. No strong relationship between mannan binding lectin or plasma ficolins and chemotherapy-related infections. Clin Exp Immunol. 2003;134:279-284.
22. Horiuchi T, Gondo H, Miyagawa H, et al. Association of MBL gene polymorphisms with major bacterial infection in patients treated with high-dose chemotherapy and autologous PBSCT. Genes Immun. 2005;6:162-166.
23. Molle NA, Peterslund S, Thiel S, et al. MBL2 polymorphism and risk of severe infections in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant. 2006;38:555-560.
24. Molle NA, Steffensen R, Thiel S, et al. Chemotherapyrelated infections in patients with multiple myeloma: associations with mannan-binding lectin genotypes. Eur J Haematol. 2006;77:19-26.
25. Klostergaard A, Steffensen R, Møller JK, et al. Sepsis in acute myeloid leukaemia patients receiving high-dose chemotherapy: no impact of chitotriosidase and mannose-binding lectin polymorphisms. Eur J Haematol. 2010;85:58-64.
26. Valdimarsson H, Vikingsdottir T, Bang P, et al. Human plasma-derived mannose-binding lectin: a phase I safety and pharmacokinetic study. Scand J Immunol. 2004;59:97-102.
27. Petersen KA, Matthiesen F, Agger T, et al. Phase I safety, tolerability, and pharmacokinetic study of recombinant human mannan-binding lectin. J Clin Immunol. 2006;26:465-475.
28. Frakking FN, Brouwer N, van de Wetering MD, et al. Safety and pharmacokinetics of plasma-derived mannose-binding lectin (MBL)substitution in children with chemotherapyinduced neutropaenia. Eur J Cancer. 2009;45:505-512.
29. Dommett R, Geary J, Freeman S, et al. Successful introduction and audit of a step-down oral antibiotic strategy for low risk paediatric febrile neutropenia in a UK, multicentre, shared care setting. Eur J Cancer. 2009;45:2843-2849.
30. Klein NJ, Kilpatrick DC. Is there a role for mannan/mannosebinding lectin (MBL) in defence against infection following chemotherapy for cancer? Clin Exp Immunol. 2004;138: 202-204.
31. Frakking FN, Brouwer N, Dolman KM, et al. Mannosebinding lectin (MBL) as prognostic factor in paediatric oncology patients. Clin Exp Immunol. 2011;165:51-59.
32. Garred P, Strom J, Quist L, et al. Association of mannosebinding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis. 2003;188:1394-1403.
33. Dalton HJ, Slonim AD, Pollack MM. Multicenter outcome of pediatric oncology patients requiring intensive care. Pediatr Hematol Oncol. 2003;20:643-649.
34. Fidler KJ, Wilson P, Davies JC, et al. Increased incidence and severity of the systemic inflammatory response syndrome in patients deficient in mannose-binding lectin. Intensive Care Med. 2004;30:1438-1445.